This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Intern Med. 2005;165:1067-1068.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Serious medical comorbidities generally preclude curative therapies for patients with leukemia. Arsenic trioxide (As₂O₃), both intravenous and oral, is highly effective for acute promyelocytic leukemia (APL).¹ As arsenic is eliminated mainly by renal excretion, uremic patients are considered unsuitable for arsenic trioxide therapy. To our knowledge, there are no data on arsenic clearance during dialysis. A patient with APL who was receiving continuous ambulatory peritoneal dialysis (CAPD) was successfully treated with oral arsenic trioxide. We took this unique opportunity to study arsenic clearance during CAPD.

Report of a Case

A 65-year-old woman with diabetes mellitus, ischemic heart disease, and chronic renal failure who was receiving CAPD had a relapse of APL 18 months after a first complete remission (CR) that had been induced with all trans-retinoic acid. She achieved a second CR (CR2) after 23 days of oral arsenic trioxide therapy (5 mg/d).² There were no significant adverse effects (normal liver . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION
Wing-Yan Au, MRCP; Giselle T. Cheung, BSc; Tommy W. Yuen, PhD; Cyrus R. Kumana, MD; Yok-Lam Kwong, MD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy
Au et al.
Blood 2008;112:3587-3590.
ABSTRACT | FULL TEXT  

Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells
Leung et al.
Blood 2007;109:740-746.
ABSTRACT | FULL TEXT  

Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety
Siu et al.
Blood 2006;108:103-106.
ABSTRACT | FULL TEXT  

Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
Au et al.
Blood 2006;107:3012-3013.
FULL TEXT